Pasithea TherapeuticsKTTA
13F holders, Q3 2024 (September 30)6holders −1
1new positions
2sold out
$5.38avg. 13F price*
At the end of Q3 2024, 6 institutions reported holding Pasithea Therapeutics Corp. (KTTA) in their 13F filings, down 1 from Q2 2024. 1 opened new positions and 2 sold out. The largest holders were UBS Group AG ($36K), Morgan Stanley ($8K) and Tower Research Capital LLC (TRC) ($3K).
- Company
- Pasithea Therapeutics Corp.
- CUSIP
- 70261F202
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $8K |
| Exits | 2 | $140K |
All 13F filers, Q2 2024 → Q3 2024: 8,041 shares bought and 28,951 shares sold, net −20,910 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 6 holders
| UBS Group AG | 0.00% | Add +17181.6% | 6,567 | $36K |
| Morgan Stanley | 0.00% | New | 1,500 | $8K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -66.7% | 601 | $3K |
| Royal Bank of Canada | 0.00% | No change | 250 | $1K |
| JPMorgan Chase & Co. | 0.00% | No change | 150 | $813 |
| Bank of America Corp. | 0.00% | Add +200.0% | 18 | $98 |
"% of holder's portfolio" is KTTA's weight in each manager's 13F, not the share of Pasithea Therapeutics Corp. the manager owns.